Document:

Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]”
and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

Amendment #3 to the Manufacturing Agreement

 

This Amendment #3 to the Manufacturing
Agreement (this “Amendment #3”) is made effective as of December 21, 2017 (“Amendment Effective Date”),
by and between ADMA BioManufacturing, LLC, a Delaware limited liability company, having a place of business at 5800 Park
of Commerce Boulevard NW, Boca Raton, Florida 33487 USA (“ADMA”) and Sanofi Pasteur S.A., a company existing
and organized under the laws of France (“Sanofi Pasteur”), having its registered head office at 14, espace Henry
Vallee, 69007, Lyon, France.

 

WHEREAS, ADMA
(as successor-in-interest to Biotest Pharmaceuticals Corporation (“BPC”) and Sanofi Pasteur are parties to that
certain Manufacturing Agreement, effective September 30, 2011, as previously amended (including by that certain Amendment #2 to
the Manufacturing Agreement, effective as of August 1, 2016, by and between BPC and Sanofi Pasteur (“Amendment #2”))
(the “Agreement”) for the production of Rabies Fraction II Paste (the “Product,” as further defined
in the Agreement) for Sanofi Pasteur from human plasma containing rabies antibodies;

 

WHEREAS, BPC
and Sanofi Pasteur are Parties to that certain Plasma Supply Agreement, effective January 20, 2009, as amended (the “Plasma
Supply Agreement”), for the production of human Rabies Hyperimmune Plasma (“Rabies Plasma”) by BPC
for Sanofi Pasteur to be used in the manufacturing of Rabies Immunoglobulin;

 

WHEREAS, the
Rabies Plasma manufactured by BPC under the Plasma Supply Agreement may be transferred to ADMA to be fractionated into Product
under the Agreement;

 

WHEREAS, ADMA
and Sanofi Pasteur desire to further amend the Agreement in order to memorialize the amendment of certain provisions in the Agreement;

 

NOW, THEREFORE,
in consideration of the respective promises contained herein and other valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto agree as follows:

 

1.       
All capitalized terms used and not defined in this Amendment shall have the meaning as set out in the Agreement.

 

2.       
The supply terms set forth in Section 1 of Amendment #2 (the “Prior Supply Terms”) are hereby deleted in their
entirety. In their place, the Parties agree to the following (and Section 2.1 of the Agreement is hereby amended as needed to implement
the following):

 

Sanofi Pasteur agrees to purchase and ADMA
to manufacture [***] Batches of Product, which Batches will be produced over a period from Q3 2018 to Q3 2019. Attached hereto
as Exhibit A is a detailed supply plan provided to ADMA by Sanofi Pasteur (the “Updated Supply Plan”) that describes
the agreed-upon timing for production of such Batches of Product, which supply plan is made an integral part hereof and shall be
binding on the Parties. Prices for such [***] Batches of Product shall be in accordance with Section 3.2 of the Agreement (as amended
in Amendment #2).

 

    
	BPC Initials ___
	Sanofi Pasteur Initials ___

1

    

    

 

Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

 

The Parties agree to amend the Agreement
to impose on ADMA an obligation to supply a minimum of [***] Batches of Product for that period stalling from Q4 2018 up to Q4
2019, as further specified in Exhibit A attached hereto.

 

Should ADMA fail to supply a minimum of
[***] Batches of Product (the “Minimum Volume”) of Product during the time period as specified in this Amendment #3,
ADMA agrees that Sanofi Pasteur shall be entitled to obtain from ADMA as liquidated damages, and not a penalty, amounting to $[***]
([***]) USD. ADMA accepts and declares that the amount of the liquidated damages is a fair and equitable compensation, and not
a penalty, for such failure in reaching the volume commitment within the timelines agreed herein and in regard to the value and
use of the Source Plasma.

 

In addition to the Minimum Volume of Product
to be manufactured by ADMA, should ADMA deliver the Minimum Volume of Product but fail to meet the Updated Supply Plan as provided
in Exhibit A as attached hereto and made an integral part hereof, then it is agreed upon by the Parties that ADMA shall pay to
Sanofi Pasteur an amount equal to $[***] ([***]) USD for each Batch of Product that is less than the agreed upon quantity in Exhibit
A, as liquidated damages, and not as a penalty.

 

The foregoing liquidated damages [***] respect to the [***]
within the [***] agreed in this Amendment #3. [***] not be entitled to [***] by this Agreement
as a result of [***], including without limitation [***].
Notwithstanding the foregoing, [***], sections 6.1 and 6.2 of the Agreement [***].

 

3.       
Furthermore, should ADMA’s compliance status under the FDA Warning Letter be escalated, and if such consequence limits
ADMA’s ability to supply the Batches of Product as specified in this Amendment #3 and the Updated Supply Plan or in case
of failure by ADMA to supply any Batch of Product under this Amendment, Sanofi Pasteur shall be entitled to terminate immediately
this Agreement upon written notice to ADMA and Sanofi Pasteur shall not be obligated to provide any additional payments (as outlined
in Section 5 below and payments for any of the unproduced or delivered production batches) to ADMA from the date of such termination.
In such a case, the remaining Source Plasma shall be immediately returned to Sanofi Pasteur, under ADMA’s liability and expenses.
Shipment of the Source Plasma to Sanofi Pasteur shall be made in compliance with the transportation conditions as provided in the
Quality Agreement (as defined below), to be further amended by the Parties as contemplated in Section 9 below.

 

    
	BPC Initials ___
	Sanofi Pasteur Initials ___

2

    

    

 

Confidential treatment
has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions
have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

4.       
In the event of a non-conformance in the Source Plasma at the time of delivery of the Source plasma at ADMA’s place,
or in the event of damaged Source Plasma, which non-conformance, damage or loss in the Source Plasma occurred prior to the transfer
of risks in the Source Plasma to ADMA as per Section 7 below, it is agreed upon by the Parties that Sanofi Pasteur shall not be
responsible, nor liable, to compensate or indemnify ADMA for the loss of business arising from the fact that, in such a case, the
Source Plasma will no longer be manufactured by ADMA and consequently Sanofi Pasteur will not pay for the unproduced batch.

 

5.       
In consideration for certain quantities of Product that ADMA would have been contractually obligated to supply, and that
Sanofi Pasteur would have been contractually obligated to purchase, under the Agreement, but that will now not be supplied and
purchased as a result of the Parties’ agreement in Section 2 above, Sanofi Pasteur agrees to pay ADMA an amount of seven
million (7,000,000 USD) (the “Compensation Fee”) in five installments and will be invoiced as follows:

 

		(a)	[***] USD upon execution of this Amendment #3

 

		(b)	[***] USD on March 1, 2018

 

		(c)	[***] USD on June 1, 2018

 

		(d)	[***] USD on September 1, 2018

 

		(e)	[***] USD on December 1, 2018

 

Such payments shall be made in accordance
with Section 3.4 of the Agreement; provided, however, that the initial payment described in Section 5(a) above shall be due no
later than December 31,2017.

 

Each invoice shall reference this Amendment
3 and shall be sent at the following address:

 

Sanofi Pasteur SA

DSFF Pole de Lyon – Carteret

Tri C5-2-01

14 Espace Henry Vallee CS 90119

69361 LYON CEDEX 07 - FRANCE

 

Upon payment of the Compensation Fee, ADMA
shall be fully compensated for any kind of prejudice or damages ADMA may suffer arising from or related to the decrease in the
quantities of Product Sanofi Pasteur committed to purchase initially from ADMA as per the Prior Supply Terms. ADMA declares that
the Compensation Fee is fair and equitable.

 

6.       
Upon full payment of the Compensation Fee, each Party, with the intention of binding itself, its Affiliates, shareholders,
successors and assigns, hereby releases, remises and forever discharges the other Party, and its Affiliates, employees, directors,
shareholders, successors and assigns, from all actions, causes of action, suits, debts, dues, sums of money, accounts, covenants,
contracts, controversies, agreements, promises, damages, claims and demands whatsoever, in law, contract or equity, arising directly
out of, or relating to the Updated Supply Plan and/or the amount of the Compensation Fee Sanofi agrees to pay to ADMA.

 

    
	BPC Initials ___
	Sanofi Pasteur Initials ___

3

    

    

 

Confidential treatment
has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions
have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

7.       
The Parties further agree to amend Section 6.5 of the Agreement as follows:

 

(a)      
The liability cap set forth under section 6.5 is hereby amended to adapt to the provisions of this Amendment #3 and is therefore
set at “[***]” instead of “[***]”.

 

(b)      
The last sentence of Section 6.5 of the Agreement is hereby deleted and replaced with the following:

 

Unless Section 2.7 applies, and
subject to any risk of loss assumed by BPC under the Plasma Agreement (as amended) or that certain [Termination, Settlement and
Release Agreement] between BPC and Sanofi Pasteur, [of even date herewith], Sanofi Pasteur assumes all risk of loss for all Source
Plasma (the “Sanofi Pasteur Property”) while under storage conditions at BPC’s warehouse except in case
such loss occurs as a result of BPC negligence or willful misconduct, and Sanofi Pasteur hereby waives any and all rights of recovery
against ADMA and its Affiliates, and against any of their respective directors, officers, employees, agents or representative,
for any loss or damage to the Sanofi Pasteur Property while under storage conditions at BPC’s warehouse. At such time that
the Source Plasma is delivered to the ADMA loading dock located at 5800 Park of Commerce Blvd NW, Boca Raton, FL 33487, risk of
loss for such delivered Source Plasma shall, as between Sanofi Pasteur and ADMA, transfer to ADMA. ADMA agrees to assume the risks
of loss to the Sanofi Pasteur Property and shall reimburse Sanofi Pasteur, at the dollar value, the Source Plasma in case of damage
or loss.

 

In consideration of the foregoing, Section
6.5 is deleted in its entirety and replaced by the following:

 

6.5 Limitation of
Liability: In no event shall either party be liable to the other party for incidental, indirect, special and consequential or punitive
damages, including without limitation any claims for damages based upon lost profits or lost business opportunity. Except for the
obligation of indemnity as set forth in Section 6.1 (c) with respect to claims by third parties for personal injury, illness or
death (but not including property damage) resulting from the manufacture of the Product by BPC, aggregate damages for which ADMA
shall be liable to Sanofi Pasteur hereunder, including without limitation costs of Source Plasma yield loss and/or rejected Batches,
shall not exceed [***]. All claims by Sanofi Pasteur for breach or default under this Agreement shall be brought within
[***] year after the cause of action comes into existence or otherwise shall be waived. This limitation of liability will
not apply for damages that result from the gross negligence or the willful misconduct of a Party.

 

    
	BPC Initials ___
	Sanofi Pasteur Initials ___

4

    

    

 

Confidential treatment
has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions
have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.

 

Furthermore, unless Section 2.7 applies,
and subject to any risk of loss assumed by BPC under the Plasma Agreement (as amended) or that certain [Termination, Settlement
and Release Agreement] between BPC and Sanofi Pasteur, [of even date herewith], Sanofi Pasteur assumes all risk of loss for all
Source Plasma (the “Sanofi Pasteur Property”) while under storage conditions at BPC’s warehouse except
in case such loss occurs as a result of BPC negligence or willful misconduct, and Sanofi Pasteur hereby waives any and all rights
of recovery against ADMA and its Affiliates, and against any of their respective directors, officers, employees, agents or representative,
for any loss or damage to the Sanofi Pasteur Property while under storage conditions at BPC’s warehouse. At such time that
the Source Plasma is delivered to the ADMA loading dock located at 5800 Park of Commerce Blvd NW, Boca Raton, FL 33487, risk of
loss for such delivered Source Plasma shall, as between Sanofi Pasteur and ADMA, transfer to ADMA. ADMA agrees to assume the risks
of loss to the Sanofi Pasteur Property and shall reimburse Sanofi Pasteur, at the dollar value, the Source Plasma in case of damage
or loss.

 

8.       
The Parties further agree to amend that certain Quality and Technical Agreement between Sanofi Pasteur and ADMA (as successor
to BPC) effective as of September 15, 2015 (the “Quality Agreement”) to modify the address where the Source Plasma
shall be stocked and the conditions associated therewith, as well as to ensure consistency with the other terms of this Amendment.
The Parties shall use best efforts to complete such amendment to the Quality Agreement within 60 days after the Amendment Effective
Date.

 

9.       
All other terms of the Agreement shall remain in full force and effect except to the extent superseded by the terms of this
Amendment #3.

 

IN WITNESS WHEREOF, the parties
hereby have caused this Amendment #3 to the Agreement to be executed and the persons signing below warrant that they are duly authorized
to sign for and on behalf of their respective Parties.

 

Made in two original copies.

 

	
        Sanofi Pasteur, S.A.

         

        By:/s/ Vincent Hingot

        Name: Vincent Hingot

        Title: Senior Vice President Industrial Affairs

        Date: 22 Dec. 2017
	
        ADMA BioManufacturing, LLC

         

        By: /s/ Adam Grossman

        Name: Adam Grossman

        Title: President & CEO

        Date: 12-21-2017

 

    
	BPC Initials ___
	Sanofi Pasteur Initials ___

5

    

    

 

Confidential treatment has been requested
with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted
and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 

 

Exhibit A

 

[***]

 

ADMA Initials ___

Sanofi Pasteur Initials ___

A-1EX-4.4

 Exhibit 4.4 

FORM OF DEBT SECURITY 
 [Face of
Security] 
 AUDENTES THERAPEUTICS, INC. 

[If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF
THIS SECURITY IS     % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS     % OF ITS PRINCIPAL AMOUNT, THE YIELD TO
MATURITY IS     % AND THE ISSUE DATE IS                ] 

[IF THE SECURITY IS A GLOBAL SECURITY, INSERT—THIS NOTE IS A GLOBAL SECURITY. IT IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF
A PERSON OTHER THAN THE DEPOSITARY (AS HEREINAFTER DEFINED) OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES HEREINAFTER DESCRIBED AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF
THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY TO A SUCCESSOR OF THE DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY.] 

 

			
	 No.
	  	$            
		  	CUSIP No.

 Audentes Therapeutics, Inc., a Delaware Corporation (herein called the “Company”, which term
includes any successor corporation under the Indenture referred to on the reverse hereof), for value received, hereby promises to pay to, or registered assigns, the principal sum
of                Dollars on                [if Security is to bear interest prior to
maturity, insert—, and to pay interest thereon from                or from the most recent Interest Payment Date to which interest has been paid or duly provided
for, semi-annually on                and                in each year,
commencing                , at the rate of     % per annum, until the principal hereof is paid or made available for payment [if applicable,
insert—, provided that any principal and premium, and any such installment of interest, which is overdue shall bear interest at the rate of     % per annum (to the extent that the payment of such interest shall be legally
enforceable), from the dates such amounts are due until they are paid or made available for payment, and such interest shall be payable on demand]. The interest so payable, and punctually paid or duly provided for, on any Interest Payment Date will,
as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Record Date for such interest, which shall be
the                or                 (whether or not a Business Day), as the case may
be, next preceding such Interest Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on such Record Date and may either be paid to the Person this Security (or one or more
Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10
days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required
by such exchange, all as more fully provided in said Indenture. [If the Security is not to bear interest prior to maturity, insert—The principal of this Security shall not bear interest except in the case of a default in payment of principal
upon acceleration, upon redemption or at Stated Maturity and in such case the overdue principal and any overdue premium shall bear interest at the rate of     % per annum (to the extent that the payment of such interest shall be
legally enforceable), from the dates such amounts are due until they are paid or made available for payment. Interest on any overdue principal or premium shall be payable on demand. [Any such interest on overdue principal or premium which is not
paid on demand shall bear interest at the rate of     % per annum (to the extent that the payment of such interest on interest shall be legally enforceable), from the date of such demand until the amount so demanded is paid or
made available for payment. Interest on any overdue interest shall be payable on demand.]]. 
 Payment of the principal of (and premium, if
any, on) and [any such] interest on this Security will be made at the office or agency of the Company maintained for that purpose in                  in such coin or
currency of [the United States of America] as at the time of payment is legal tender for payment of public and private debts[; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address of the
Person entitled thereto as such address shall appear in the Register]. 
 Reference is hereby made to the further provisions of this
Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place. 

Unless the certificate of authentication hereon has been manually executed by or on behalf of the Trustee under the Indenture referred to on
the reverse hereof, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

  
 II-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its
corporate seal. 
  

					
	Dated:	  	Audentes Therapeutics, Inc.
			
		  	By	  	  

		  		  	[Title]
	Attest and Countersign	  	
		
	  
	  	
	Secretary	  	

  
 II-2 

 [Reverse of Security.] 

AUDENTES THERAPEUTICS, INC. 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be
issued in one or more series under an Indenture dated as of                 , (herein called the “Indenture,” which term shall have the meaning assigned to it
in such instrument), between the Company and                , as trustee (herein called the “Trustee”, which term includes any successor trustee under the
Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations or rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the
Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof [, limited in aggregate principal amount to
$                ]. 
 [If the Security is to be
subordinated, insert—The indebtedness evidenced by this Security is, to the extent and in the manner set forth in the Indenture, expressly subordinated and subject in right of payment to the prior payment in full of all Senior Indebtedness (as
defined in the Indenture) of the Company. This Security is issued subject to such provisions of the Indenture, and each Holder of this Security, by accepting the same, agrees to and shall be bound by such provisions and authorizes and directs the
Trustee on the Holder’s behalf to take such action as may be necessary or appropriate to acknowledge or effectuate such subordination as provided in the Indenture and appoints the Trustee such Holder’s attorney-in-fact for any and all such purposes.] 
 The Securities of this series are subject to
redemption upon not less than 30 days’, and no more than 60 days, notice provided in the manner set forth in the Indenture, [(1) on in any year commencing with the year and ending with the year at the Redemption Price equal to 100% of the
principal amount, and (2)] at any time [on or after], as a whole or in part, at the election of the principal the following Redemption Prices (expressed as percentages of the principal amount): If redeemed [on or before ,     %,
and if redeemed] during the 12-month period beginning of the years indicated, 
  

													
	 Year
	  	Redemption Price	 	  	Year	 	  	Redemption Price	 
		  				  				  			

 and thereafter at a Redemption Price equal to     % of the principal amount together in the case of any
such redemption with accrued interest to the Redemption Date, but interest installments whose Stated Maturity is on or prior to such Redemption Date will be payable to the Holders of such Securities of record at the close of business on the relevant
record dates referred to on the face hereof, all as provided in the Indenture. 
 [If the Security is to be redeemable in part,
insert—In the event of redemption of this Security in part only, a new Security or Securities of this series for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.] 

[If the Security is to be subject to repayment at the option of the Holder, insert—To be repaid at the option of the Holder, the Company
must receive this Security, with the form of “Option to Elect Repayment” hereon duly completed, at an office or agency of the Company maintained for that purpose in (or at such other place of which the Company shall from time to time
notify the Holder of this Security) not less than nor more than days prior to the Repayment Date. The exercise of the repayment option by the Holder shall be irrevocable.] 

[If the Security is not to be subject to redemption at the option of the Company, insert—The Securities are not redeemable at the option
of the Company prior to Maturity.] 
 [If the Security is not to be an Original Issue Discount Security, insert—If an Event of Default
with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.] 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations
of the Company and the rights of the Holders of the Securities of each series under the Indenture to be affected at any time by the Company with the consent of the Holders of not less than a majority in aggregate principal amount of the Securities
at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all
Securities of such series, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the 

 Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this
Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent of waiver is made upon this Security. 

As provided in and subject to the provisions of the indenture, the Holder of this Security shall not have the right to institute any
proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to
the Securities of this series , the Holders of not less than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the trustee to institute proceedings in respect of such Event of Default
as Trustee and offered the Trustee reasonable indemnity satisfactory to it, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction inconsistent with
such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement
of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein. 
 No reference
herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of (and premium, if any, on) and interest on this Security
at the times, place and rate, and in the coin or currency, herein prescribed. 
 [If the Security is to be in registered form,
insert—As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Register, upon surrender of this Security for registration of transfer at the office or agency of the
Company in any place where the principal of (and premium, if any, on) and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar duly executed
by, the Holder hereof or his attorney duly authorized in writing, and, thereupon one or more new Securities of this series, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or
transferees.] 
 [The Securities of this series are issuable only in registered form in denominations of $ [and any integral multiple]
[or increments of $ in excess] thereof. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series of a
different authorized denomination, as requested by the Holder surrendering the same.] 
 [No service charge shall be made for any such
registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.] 

[Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee
may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.] 

[If the Security is a Global Security, insert—“Global Security” and “Global Securities” means a Security or
Securities evidencing all or a part of a series of Securities, issued to the Depositary (as hereinafter defined) for such Series or its nominee, and registered in the name of such Depositary or its nominee. “Depositary” means, with
respect to the Securities of any series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as the Depositary by the Company. 

No holder of any beneficial interest in this Security held on its behalf by a Depositary or a nominee of such Depositary shall have any rights
under the Indenture with respect to such Global Security, and such Depositary or nominee may be treated by the Company, the Trustee, and any agent of the Company or the Trustee as the owner of such Global Security for all purposes whatsoever.
Notwithstanding the foregoing, nothing herein shall impair, as between a Depositary and such holders of beneficial interests, the operation of customary practices governing the exercise of the rights of the Depositary as Holder of any Security. 

This Security is exchangeable, in whole but not in part, for Securities registered in the names of Persons other than the Depositary or its
nominee or in the name of a successor to the Depositary or a nominee of such successor depositary only if (i) the Depositary notifies the Company that it is unwilling or unable to continue as Depositary for this Note or if at any time such
Depositary ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended, and, in either case, a successor depositary is not appointed by the Company within 90 days, (ii) the Company in its discretion at any
time determines not to have all of the Securities of this series represented by one or more Global Security or Securities and notifies the Trustee thereof, or (iii) an Event of Default has occurred and is continuing with respect to the
Securities of this series. If this Security is exchangeable pursuant to the preceding sentence, it shall be exchangeable for Securities issuable in authorized denominations and registered in such names as the Depositary holding this Security shall
direct. Subject to the foregoing, this Security is not exchangeable, except for a Security or Securities of the same aggregate denominations to be registered in the name of such Depositary or its nominee or in the name of a successor to the
Depositary or a nominee of such successor depositary.] 

 [The Indenture entitles Holders to receive annual reports with respect to the Trustee’s
eligibility and qualifications to serve as Trustee by filing their names and addresses with the Trustee for that purpose within two years preceding and mailing of any such annual report.] 

No recourse shall be had for the payment of the principal of (and premium, if any, on) or interest on this Security, or for any claim based
hereon, or otherwise in respect hereof, or based on or in respect of the Indenture of any indenture supplemental thereto, against any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or any successor
corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issue
hereof, expressly waived and released. 
 All terms used in this Security which are defined in the Indenture shall have the meanings
assigned to them in the Indenture. 
 This Security, including without limitation the obligation of the Company contained herein to pay the
principal of (and premium, if any, on) and interest on this Security in accordance with the terms hereof and of the Indenture, shall be construed in accordance with and governed by the laws of the State of New York. 

 

			
	 [Trustee’s Certificate of Authentication.]

	
	 This is one of the Securities of the series designated herein referred to in the
within-mentioned Indenture.

	
	             
                                 , as

	 [Authenticating Agent for] the Trustee

		
	 By
	  	                                     
                                         
                              
		  	 Authorized Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]